Breaking News Instant updates and real-time market news.

ACOR

Acorda Therapeutics

$20.65

0.05 (0.24%)

09:33
11/30/16
11/30
09:33
11/30/16
09:33

Acorda Therapeutics upgraded to Overweight from Neutral at JPMorgan

JPMorgan analyst Cory Kasimov upgraded Acorda Therapeutics to Overweight from Not rated and Neutral prior to the restriction. The analyst said upcoming Phase 3 data for CVT-301 and a decision in the pending Ampyra IP cases have the potential to act as catalysts.

ACOR Acorda Therapeutics
$20.65

0.05 (0.24%)

03/30/16
GSCO
03/30/16
DOWNGRADE
Target $10
GSCO
Neutral
Dimension Therapeutics downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Salveen Richter downgraded Dimension Therapeutics (DMTX) to Neutral saying other names in the sector offer better near-term opportunities. The analyst views Dimension as well-positioned in the gene therapy space, however. He lowered his price target for the shares to $10 from $12. Richter this morning also initiated SAGE Therapeutics (SAGE) with a Buy rating and Acorda Therapeutics (ACOR) with a Sell rating.
03/30/16
03/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Intercept (ICPT) initiated with an Outperform and a Neutral at Credit Suisse and Goldman, respectively. Goldman Sachs analyst Salveen Richter said investor expectations into the April 7 FDA panel for obeticholic acid in primary biliary cholangitis appear high. 2. Acorda Therapeutics (ACOR) initiated with a Sell at Goldman by analyst Salveen Richter, who said Acorda's lead product Ampyra is close to fully realizing its commercial opportunity and that intellectual property threats will present an overhang on the shares. 3. SAGE Therapeutics (SAGE) initiated with a Buy at Goldman due to the belief that the company is a key player in acute central nervous system disorders. 4. Rio Tinto (RIO) initiated with a Buy at Argus. 5. Square (SQ) initiated with a Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
LEER
10/04/16
INITIATION
Target $25
LEER
Market Perform
Acorda Therapeutics reinstated with a Market Perform at Leerink
Leerink analyst Paul Matteis resumed coverage of Acorda Therapeutics with a Market Perform rating and $25 price target.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.